FungiScope - A Global Emerging Fungal Infection Registry
ConditionInvasive Fungal Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Cologne
About this trial
The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Cultural, histopathological, antigen or DNA evidence of invasive fungal infection
Disqualifiers
Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci
Endemic fungal infection such as coccidioidomycosis or histoplasmosis
Colonisation or other non-invasive infection
Trial population
Invasive infections caused by emerging fungi
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,000 Participants
are grouped into 1 trial groupGroup A: Emerging fungal infections
Trial outcomes
Primary outcomes
1
Treatment efficacy of emerging fungal infections
failure, stable disease, partial response or complete response
Time frame
At 90 days from diagnosisSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Cologne
Lead sponsor
Pfizer
Collaborator
Basilea Pharmaceutica
Collaborator
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborator
F2G Biotech GmbH
Collaborator
Matinas Biopharma, Inc
Collaborator
Source ClinicalTrials.gov